2sev­en­ty inks T cell part­ner­ship with Chi­nese biotech; An­ti­sense drug caus­es brain side ef­fect — re­port

2sev­en­ty bio has se­cured an I/O deal with a Chi­nese biotech.

The blue­bird bio spin­out, which formed last year, an­nounced a deal Thurs­day morn­ing with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.